much better expect updat model ep estim
rais year sale estim chang mix much clinic
news good pipelin visibl plan return capit sharehold key
friday increas ep estim guidanc
today increas estim
ep project intact
ep compound-annual-growth-rate versu previous guidanc
suggest double-digit ep growth
increas sale estim versu guidanc
approach thereaft increas estim
clip forecast
project increas ep compound-annual-growth-rate
versu previous
humira forecast increas
manag guidanc imbruvica estim increas
although bit guidanc base
great start better expect perform mavyret project
increas decreas significantli
gross-to-net adjust reflect show line drag revenu
given humira expect incur biosimilar competit
forecast oper margin well guidanc
year deliv margin would add ep
line guidanc forecast tax rate rise year thereaft
reach last publish forecast explain
effici tax structur put gener in-lin tax rate
approxim global minimum gilti tax abbv tax rate
guidanc also factor impact foreign tax credit time
expect tax rate increas given higher incom invest
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit hepat
segment oncolog compani pipelin promis agent
opportun upward revis sever front stock attract valu
versu group overal much lower-than-expect tax rate add appeal
attribut argu purchas share
updat sharehold return post
rova-t data/fil sclc mid
mavyret nex-gen hcv rollout
elagolix approv endometriosi
humira sale
biosimilar competit
humira biosimilar gain traction
quickli eu and/or launch
especi oncolog
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
time frameev upadacitinib phase data ra select-compar select-earli initi phase atop dermat phase gca ucelagolix w/neurocrin phase top-lin data uterin fibroid illumin data unfit cll/sllphase phoenix data dlbclfull phase selen data r/r fl/mzlphase ii resolv data pancreat cancerrisankizumab phase psainiti phase ucrova-tphas ii top-lin data triniti sclc data net basket trialphas data r/r sclc w/nivo /- ipiveliparibphas vela data non-sq nsclcvenclexta w/roch initi phase mm maintenancephas ii data r/r fl w/rituxan contralto phase ii data dlbcl w/rchop caval initi phase r/r/ fl dlbcl ph ii positivevenclexta imbruvicainiti phase wm upadacitinib regulatori file ra w/neurocrin approv endometriosi file dlbclimbruvica rituxanregulatori file wmrisankizumab file psoriasi eu filings/approv venclexta w/roch /eu approv r/r cll w/rituxanu file aml late cowen
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold till post settlement potenti other humira biosimilar anticip enbrel foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi guidelin chang could pressur use adopt ou foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launch franchiseandrogel testosteron gel hypergonad market declinekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir inhibitor hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex delet indic approv standard refractori file venetoclax select inhibitor cllelagolix- oral gnrh antagonist partial estrogen suppress endometriosi file ph uterin fibroid partnership neurocrin eign lc ex similar lupron zoladexelagolix hold ww right elagolix gnrh antagonistsrova-t triniti data sclc file eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close daclizumab alpha mab q-monthli inj efficaci rem program requir market zenepax kidney x-plant reject roch eign lc ex efficaci profil posit salvag tx jcv ms patient zinbryta acquir via facet biotech partner w/biib guidanc phase psoriasi phase ii crohn pa eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib guidanc file base studi atop dermat data eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl foreign lc ex trial fail glioblastoma filingveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase pipelin foreign lc ex foreign lc ex guidanc annual revenu growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
